P. M. Cannon

This paper describes a genome editing strategy to reprogram human B cells to express custom heavy chain antibodies that respond to immunization.

This study compares ACE2-derived and engineered Spike-binding peptide entry inhibitors against SARS-CoV-2 variants, finding that an optimized ACE2 derivative neutralizes all tested variants, while peptides show variable efficacy with resistance observed in Beta, Gamma, and Omicron variants.

This study shows that truncating the SARS-CoV-2 Spike protein's cytoplasmic tail increases pseudovector titer but masks the D614G mutation's effect on Spike incorporation.